Advice

In the absence of a submission from the holder of the marketing authorisation

panitumumab (Vectibix) is not recommended as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS (Kirsten rat sarcoma 2 viral oncogene homologue) after failure of fluoropyrimidine -, oxaliplatin -, and irinotecan - containing chemotherapy regimens.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice51KB (PDF)

Download

Medicine details

Medicine name:
panitumumab 20mg/ml concentrate for solution for infusion (Vectibix)
SMC ID:
486/08
Indication:
as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma
Pharmaceutical company
Amgen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Superseded
Date advice published
09 June 2008
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Clinical Excellence (NICE) Multiple Technology Appraisal (MTA)